Loading...
Please wait, while we are loading the content...
Similar Documents
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Mogensen, Carl Erik Viberti, Giancarlo Halimi, Serge Ritz, Eberhard Ruilope, Luis M. Jermendy, György Widimský, Jiří Sareli, Pinchas Tatoń, Jan Rull, Juan Erdoğan, Gürbüz Leeuw, Pieter W. De Ribeiro, Artur Beltrame Mechmèche, Rachid Nolan, John Sirotiaková, Jana Hamani, Ahmed Scheen, André Hess, Bernhard Luger, Anton Thomas, Stephen M. |
| Copyright Year | 2003 |
| Abstract | Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month, randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2 diabetes and hypertension (systolic BP > or =140 mm Hg, <180 mm Hg, diastolic BP <110 mm Hg) were randomly assigned (age 59+/-9 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat analysis) were available. After a 4-week placebo period, patients with albuminuria >20 and <500 microg/min were randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week 12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril. The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (-3.0 [95% CI -5.6, -0.4], P=0.012; systolic BP -1.5 [95% CI -3.0, -0.1] diastolic BP P=0.019) and AER -42% (95% CI -50%, -33%) versus -27% (95% CI -37%, -16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect of the combination may increase renal protection. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://hyper.ahajournals.org/content/hypertensionaha/41/5/1063.full.pdf |
| Alternate Webpage(s) | http://orbi.ulg.ac.be/bitstream/2268/2077/1/Scheen_A_2003_hyp_1063.pdf |
| PubMed reference number | 12654706v1 |
| Volume Number | 41 |
| Issue Number | 5 |
| Journal | Hypertension |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Cessation of life Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Diastole Dietary Mercury Enalapril Hypertensive disease Indapamide Patients Perindopril Erbumine PersonNameUse - assigned |
| Content Type | Text |
| Resource Type | Article |
